Stock Market

Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results

By Bullbit Editorial · March 26, 2026

WhatSarepta shares surged **35%** after Morgan Stanley raised its price target.
WhyThe hike was driven by stellar trial results and a positive outlook on the company's gene therapy pipeline.
SignalThe stock's significant gain is a strong signal to investors that Sarepta's gene therapy is gaining traction.
TargetMorgan Stanley's new price target indicates a high level of confidence in the company's future growth prospects.
RiskThe stock's rapid ascent may pose a risk to investors who have not yet adjusted their portfolios.